基因与疾病(英文)(Genes & Diseases)

基因与疾病(英文)(Genes & Diseases) 知网目次万方目次维普目次

  • CSCD
  • 科核
基本信息
  • 主管单位:

    重庆市教育委员会

  • 主办单位:

    重庆医科大学

  • 国际刊号:

    2352-4820;EISSN2352-3042

  • 国内刊号:

    50-1221/R

  • 学科分类:

    医卫综论

  • 字数:

    6000-42000

  • 有无基金:

    /有基金 100.0%

  • 周期:

    CN外文-双月刊

  • 特殊属性:

    外文期刊

联系信息
  • 电话:

    023-65714691(官网电话)

  • 邮箱:

    editor@genesndiseases.com(官网邮箱)

  • 复合因子:

    0

  • 综合因子:

    0

  • 收录:

    知网目次,万方目次,维普目次

  • 级别:

    CSCD,科核

期刊简介

《基因与疾病(英文)(Genes & Diseases)》期刊已被查看:

更新频次

单位占比

一作占比

/有基金-100.0%

投稿指南

1、投稿方式:在线投稿。

2、官网网址:http://www.genesndiseases.com/

https://www.sciencedirect.com/journal/genes-and-diseases

3、投稿网址:https://www.editorialmanager.com/GENDIS

4、官网邮箱:editor@genesndiseases.com(编辑部)

5、官网电话:023-65714691(编辑部)

6、出刊日期:双月刊,逢单月出版。

2024年4月18日星期四

Genes & Diseases 融合出版官方网站上线啦!

【微信公众号“重庆医科大学(cqmu1956)”信息】

重庆医科大学 2023-12-19 15:12 重庆

Genes & Diseases  融合出版

官方网站上线

为了更好的服务广大专家和读者用户,提升用户使用体验,增加期刊与各位用户朋友的沟通与连接,经过前期精心策划和筹备以及不断修改和测试,在SD官方网站的基础上,Genes & Diseases自建官网经升级改版,推出全新融合出版中英文官方网站。新版网站于2023年12月7日正式成功上线,以全新的姿态和面貌迎接即将到来的创刊十周年。

新版官网从顺应互联网发展趋势,彰显期刊特色,完善功能、优化布局、增加互动等方面做了深度升级,同时突出以“图-文-视-听”四位一体的呈现形式,能够更方便快捷的浏览获取期刊论文、主题专辑、人物专访以及科普文章等资讯。

全新融合出版官网入口:

http://www.genesndiseases.com/

ScienceDirect官方网站:

https://www.sciencedirect.com/journal/genes-and-diseases

新网站,新风貌,在此衷心感谢各位专家和读者的关注和支持!期待在各位持续支持和关注下,Genes & Diseases 全新官方网站能够成为一个更好的交流互动平台。

《基因与疾病(英文)》投稿指南

【官网信息】

Guide for Authors

Introduction

About the Journal

Genes & Diseases is an international journal for molecular and translational medicine. The journal primarily focuses on publishing investigations on the molecular bases and experimental therapeutics of human diseases. Publication formats include full length research article, review article, rapid communication, correspondence, perspectives, commentary, views on news, research watch, letters, research highlights, and enabling and emerging technologies.

Editorial Process

All manuscripts received are duly acknowledged. Upon submission, the Editorial Office will check the manuscript's conformity to technical quality and author guidelines, typically within one week. Manuscripts with insufficient conformity are returned to authors for revision. Manuscripts with insufficient originality, serious scientific or experimental flaws, or lack of interest to the readership of Genes & Diseases will be rejected by the Editor-in-Chief and/or Deputy Editor-in-Chief without further peer review. Manuscripts deemed suitable for publication are sent to the Executive Associate Editors. The Executive Associate Editors will make initial assessment and will serve as the managing editor, who in turn will appoint 2-3 editorial board members and/or external referees to complete peer reviews within 4 weeks. Based on the recommendations and comments made by peer reviewers, the Executive Associate Editor will make a formal recommendation to the Editor-in-Chief and/or Deputy Editor-in-Chief who will make the final decision within 1 week, in consultation with other editorial board members, if deemed necessary. The comments and recommendations (acceptance/ rejection/ minor revision/ major revision in manuscript) received from reviewers are conveyed to the corresponding author. If necessary, the author is required to provide a point by point response to reviewers' comments and submit a revised manuscript. This process will be repeated till reviewers and editors are satisfied with the revised manuscript.

Manuscripts accepted for publication are copy edited for grammar, punctuation, print style, and format. Page proofs are sent to the corresponding author. The corresponding author is expected to return the corrected proofs within 48 hours. The whole process of submission of the manuscript, final decision, sending and receiving proofs is completed online. To achieve faster and greater dissemination of knowledge and information, the journal publishes articles online as 'Ahead of Print' immediately upon acceptance.

During submission, the contributor is requested to provide names of at least three qualified reviewers who have had experience in the subject of the submitted manuscript. The reviewers should not be affiliated with the same institutes as the contributor/s. However, the selection of these reviewers is at the sole discretion of the editor.

Contact Details for Submission

Papers should be submitted through the Genes & Diseases online submission system, https://www.editorialmanager.com/GENDIS. For questions on the submission and reviewing process, please contact the Editorial Office at: editor@genesndiseases.com; telephone +86-23-6571 4691.

更多详情请查看期刊官网信息。

中国全科医学发文选摘

  • 1、2019.V1版《NCCN结直肠癌诊治指南》更新要点解析
  • 1、2019.V1版《NCCN结直肠癌诊治指南》更新要点解析
  • 1、2019.V1版《NCCN结直肠癌诊治指南》更新要点解析
  • 1、2019.V1版《NCCN结直肠癌诊治指南》更新要点解析
  • 1、2019.V1版《NCCN结直肠癌诊治指南》更新要点解析
  • 1、2019.V1版《NCCN结直肠癌诊治指南》更新要点解析
  • 1、2019.V1版《NCCN结直肠癌诊治指南》更新要点解析
  • 1、2019.V1版《NCCN结直肠癌诊治指南》更新要点解析
  • 1、2019.V1版《NCCN结直肠癌诊治指南》更新要点解析
  • 1、2019.V1版《NCCN结直肠癌诊治指南》更新要点解析
  • 1、2019.V1版《NCCN结直肠癌诊治指南》更新要点解析
  • 1、2019.V1版《NCCN结直肠癌诊治指南》更新要点解析
  • 1、2019.V1版《NCCN结直肠癌诊治指南》更新要点解析
  • 1、2019.V1版《NCCN结直肠癌诊治指南》更新要点解析
  • 1、2019.V1版《NCCN结直肠癌诊治指南》更新要点解析
  • 1、2019.V1版《NCCN结直肠癌诊治指南》更新要点解析
  • 1、2019.V1版《NCCN结直肠癌诊治指南》更新要点解析
  • 1、2019.V1版《NCCN结直肠癌诊治指南》更新要点解析
  • 1、2019.V1版《NCCN结直肠癌诊治指南》更新要点解析
  • 1、2019.V1版《NCCN结直肠癌诊治指南》更新要点解析

常见问题

  • 哪些期刊可以用来评职称?

    1、期刊要具备正规性和合法性,需在国家新闻出版总署备案,具备国内刊号(cn)。2、期刊要具备学术性,例如该期刊需被国内主流学术、数据库收录,例如被知网,万方,维普收录。具体详情可以咨询我们的客服老师为您解答。

  • 你们的服务可以保证文章被发表吗?

    期刊发表的成功与否,主要取决于文章内容的质量。期刊编辑会根据研究领域、创新性等多因素进行考量。我们会帮助您理解期刊的发表要求,助力提升发表几率,从而增加发表的机会。

  • 请问发表一篇期刊的费用是多少?

    期刊的种类繁多,其费用也各不相同。根据您的需求,将为您推荐最具性价比的期刊,让您能更便捷地找到心仪的期刊。一般来说,只要符合职称评定要求的,大多数作者都会选择性价比最高的期刊作为首选目标。

  • 如果发表不成功可以退款吗?

    如果因为我方原因导致未能发表成功,我们将全额退还相关费用。需要明确的是,稿件能否发表主要取决于期刊的独立考量。为了提升您的发表几率,我们会提供专业的指导和支持,帮助您避免拒稿,并助力提高您的稿件质量。

  • 请问文章发表需要多长时间?

    不同级别的期刊发表时间是不一样的。无论是普刊还是核心期刊,建议您提前准备。普刊需提前3-6个月,而核心期刊需提前一年左右。为确保职称评定流程顺利进行,建议您提前半年到一年进行准备,以免错过申请的最佳时机。

  • 期刊发表能加急见刊吗?

    为了确保顺利发表,建议您提前一些时间进行安排。本站仅提供投稿发表咨询服务,需要用户自己向出版商投稿且没有绿色通道,是否录用一切以出版商通知为准。